Literature DB >> 16265598

Bone remodeling at the iliac crest can predict the changes in remodeling dynamics, microdamage accumulation, and mechanical properties in the lumbar vertebrae of dogs.

T Mashiba1, S Hui, C H Turner, S Mori, C C Johnston, D B Burr.   

Abstract

We previously demonstrated that suppression of bone remodeling allows microdamage to accumulate, thereby leading to reduced bone toughness in dog bone. In this study we evaluated the relationships between bone remodeling at the iliac crest and skeletal activation frequency, microdamage accumulation, or biomechanical properties of lumbar vertebrae using the same dogs to determine whether bone remodeling at the iliac crest can predict damage accumulation and mechanical parameters of the lumbar spine following treatment with antiresorptive agents. Thirty-six female beagles, 1 to 2 years old, were divided into three groups. The control group was treated daily for 12 months with saline vehicle. The remaining two groups were treated daily with oral risedronate at a dose of 0.5 mg/kg/day, or alendronate at 1.0 mg/kg/day orally. The doses of these bisphosphonates were 5 to 6 times the clinical doses approved for treatment of osteoporosis in humans. After sacrifice, the right ilium and L2 vertebra were assigned to histomorphometry. The left ilium and L3 vertebra were used for microdamage analysis. The L4 vertebra was mechanically tested to failure in compression, and bone toughness calculated from the stress-strain curve. There was a strong positive relationship for activation frequency (Ac.f) between ilium and lumbar vertebrae (r2 = 0.82; P < 0.0001). Iliac crest Ac.f underestimates Ac.f in L2, but L2 Ac.f reaches a minimum threshold and does not decline further when iliac crest Ac.f is below 0.10/yr. Microdamage (Cr.S.Dn) accumulation at the ilium was significantly associated with increased microdamage accumulation in the L3 lumbar vertebra (r2 = 0.43, P < 0.0001). The data also show that bisphosphonate treatment increased Cr.S.Dn at a faster rate in L3 than in the iliac crest. Although bisphosphonate treatment decreased bone toughness in L4, this decrease demonstrated no relationship to decreased Ac.f in the ilium. These results clearly indicate that bone remodeling data obtained from iliac crest biopsy could be used to estimate the activation frequency and microdamage burden in the vertebral column.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16265598     DOI: 10.1007/s00223-005-1295-x

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  9 in total

1.  Bisphosphonate-associated femur fractures have high complication rates with operative fixation.

Authors:  Mark L Prasarn; Jaimo Ahn; David L Helfet; Joseph M Lane; Dean G Lorich
Journal:  Clin Orthop Relat Res       Date:  2012-06-06       Impact factor: 4.176

2.  Assessment of a bone biopsy technique for measuring tiludronate in horses: a preliminary study.

Authors:  Catherine Delguste; Michèle Doucet; Annick Gabriel; Jérôme Guyonnet; Olivier M Lepage; Hélène Amory
Journal:  Can J Vet Res       Date:  2011-04       Impact factor: 1.310

3.  Can long-term bisphosphonate use causes low-energy fractures? A case report.

Authors:  T Dandinoğlu; S Akarsu; M Karadeniz; L Tekin; S Arıbal; M Z Kıralp
Journal:  Osteoporos Int       Date:  2013-07-04       Impact factor: 4.507

4.  Morphology, localization and accumulation of in vivo microdamage in human cortical bone.

Authors:  Tamim Diab; Deepak Vashishth
Journal:  Bone       Date:  2006-11-13       Impact factor: 4.398

5.  Changes in non-enzymatic glycation and its association with altered mechanical properties following 1-year treatment with risedronate or alendronate.

Authors:  S Y Tang; M R Allen; R Phipps; D B Burr; D Vashishth
Journal:  Osteoporos Int       Date:  2008-10-11       Impact factor: 4.507

6.  Role of microcracks in the pathogenesis of bisphosphonate-related osteonecrosis of the jaw.

Authors:  Jin-Woo Kim; Maria Erika A Landayan; Ju-Young Lee; Jacquiline Czar I Tatad; Sun-Jong Kim; Myung-Rae Kim; In-Ho Cha
Journal:  Clin Oral Investig       Date:  2016-01-22       Impact factor: 3.573

7.  Alendronate treatment results in similar levels of trabecular bone remodeling in the femoral neck and vertebra.

Authors:  T Diab; M R Allen; D B Burr
Journal:  Osteoporos Int       Date:  2008-08-21       Impact factor: 4.507

8.  Cancer treatment dosing regimens of zoledronic acid result in near-complete suppression of mandible intracortical bone remodeling in beagle dogs.

Authors:  Matthew R Allen; Daniel J Kubek; David B Burr
Journal:  J Bone Miner Res       Date:  2010-01       Impact factor: 6.741

9.  Tiludronate and clodronate do not affect bone structure or remodeling kinetics over a 60 day randomized trial.

Authors:  Heather A Richbourg; Colin F Mitchell; Ashley N Gillett; Margaret A McNulty
Journal:  BMC Vet Res       Date:  2018-03-20       Impact factor: 2.741

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.